2. RRMS diagnosis according to revised McDonald 2017 criteria
3. First MS symptom \>5 years ago. If the date is unknown, RRMS diagnosis \>5 years ago
4. Stable disease in the last 5 years according to the revised Lublin and Reingold classification characterized by :
Stable T2 lesions documented by MRI performed at least 5 years prior to inclusion versus MRI performed within 6 months prior to the inclusion visit, AND Stable EDSS documented at least 5 years prior to inclusion versus EDSS documented within 6 months prior to inclusion visit, according to the investigator's judgment, AND The absence of relapses within 5 years prior to the inclusion visit
5. Treated with a Moderate Efficacy Therapy (MET) for at least 5 consecutive years (IFN-β, glatiramer acetate, dimethyl fumarate, teriflunomide, diroximel fumarate); switching from one first-line treatment to another is accepted if the reason for the change is related to personal convenience or intolerance to the first treatment.
6. Patient with affiliation to a social security regimen
7. Patient able to understand the objectives and risks associated with the research and to give informed consent to the study
8. Patient willing and able to comply with study procedures for the duration of the study
You may not be if
1. Primary progressive or secondary progressive with or without relapse as defined by the revised Lublin and Reingold classification
2. Previous or ongoing treatment with a High Efficacy therapy (HET), with the exception of induction therapy (mitoxantrone, stem cell transplantation, alemtuzumab) provided that the last administration took place at least 10 years prior to inclusion.
3. Contraindication to MRI (claustrophobia, weight ≥ 140 kg, pacemaker, cochlear implants, foreign body in eye, intracranial vascular clips, surgery in the 6 weeks prior to the beginning of the study, coronary stent implanted in the 8 weeks prior to the beginning of the study,…).
NB : Gadolinium contraindication will not prevent recruitment of the patient; in this case MRI will be carried out without contrast product injection
4. History of neurological disease affecting the central nervous system: hereditary degenerative CNS disease, degenerative cognitive disease, systemic autoimmune disease, sarcoidosis, Lyme disease…
5. Chronic disease which requires chronic treatment with corticoids or immunosuppressors
6. Uncontrolled cardiac, renal or hepatic disease
7. Patient participating in another interventional trial (drug or a medical device) or patient who are still within an exclusion period
8. Patient wishing to discontinue background therapy, whether or not they are experiencing adverse effects.
9. Patient not considering discontinuing background therapy, whether or not they are experiencing adverse effects.
10. Pregnant or breastfeeding woman
11. Patient with difficulty to read or understand French,
12. Patient subject to a legal protection measure
Clareo Health | Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
